3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms by Site
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neoplasms
1
Lung Diseases
1
Head and Neck Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Bronchial Neoplasms
1
Interventions
Carboplatin
23
Cisplatin
19
pembrolizumab
14
Paclitaxel
13
Gemcitabine
12
Pemetrexed
11
130-nm albumin-bound paclitaxel
9
Everolimus
8
Cetuximab
8
Fluorouracil
7
Docetaxel
6
Axitinib
6
Albumin-Bound Paclitaxel
6
osimertinib
5
durvalumab
5
Sunitinib
5
Radiotherapy
5
Nivolumab
5
Erlotinib Hydrochloride
5
Cyclophosphamide
5
Sorafenib
4
Radiation
4
Irinotecan
4
Ipilimumab
4
vosaroxin
3
Radiotherapy, Intensity-Modulated
3
Octreotide
3
Bevacizumab
3
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
3
trifluridine tipiracil drug combination
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma
×
patritumab
×
Clear all
NCT02134015
2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3
Terminated
145 enrolled
20 charts